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Abstract
The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have
been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1,
derived from proteoliposomes of N. meningitidis B) using a dialysis procedure to produce them on lab scale. The
immunogenicity of the AFCo1 produced by dialysis has been already evaluated, but it was necessary to demonstrate
the feasibility of a larger-scale manufacturing process. Therefore, we used a crossflow diafiltration system (CFS) that
allows easy scale up to obtain large batches in an aseptic environment. The aim of this work was to produce AFCo1
on pilot scale, while conserving the adjuvant properties. The proteoliposomes (raw material) were resuspended in a
buffer containing sodium deoxycholate and were transformed into AFCo1 under the action of a calcium forming
buffer. The detergent was removed from the protein solution by diafiltration to a constant volume. In this CFS, we
used a hollow fiber cartridge from Amicon (polysulfona cartridge of 10 kDa porosity, 1mm channel diameter of fiber
and 0.45 m2 area of filtration), allowing production of a batch of up to 20 L. AFCo1 were successfully produced by
tangential filtration to pilot scale. The batch passed preliminary stability tests. Nasal immunization of BALB/c mice,
induced specific saliva IgA and serum IgG. The induction of Th1 responses were demonstrated by the induction of
IgG2a, IFNg and not IL-5. The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous)
antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated.
Background
Over the last decade, there has been a flurry of research
on adjuvants for vaccines, and several novel adjuvants are
now in licensed products or in late clinical stage develop-
ment. The success of adjuvants in enhancing the immune
response to recombinant antigens has led many research-
ers to re-focus their vaccine development programs.
Successful vaccine development requires knowing which
adjuvants to use and knowing how to formulate adju-
vants and antigens to achieve stable, safe and immuno-
genic vaccines. In addition to the demonstration of
safety, immunogenicity and protection in preclinical
models (where a model exits) and clinical studies, any
adjuvant system needs to demonstrate feasibility of large-
scale manufacturing. This includes definition, selection,
supply and characterization of the raw materials, as well
as the development of production processes that will
deliver a stable and consistent product. In order to reach
the final product, manufacturing processes, analytical
and immunological tools, and quality control testing
need to be conducted successfully. Only through this
strict and controlled process will the quality of future
adjuvant vaccines be guaranteed [1]. In this work,
we transformed Neisseria proteoliposomes into cochleate
structures (AFCo1) using a cross flow filtration system
(CFS). AFCo1 showed high stability, immunogenicity and
adjuvant effect on heterologous co-administered antigens
[2]. Obtaining AFCo1 by tangential filtration process
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would ensure the production of a large scale batch of a
safe and immunogenic adjuvant.
Materials and methods
Raw materials and filtration
Proteoliposomes were prepared from the outer mem-
branes of serogroup B N. meningitidis strain Cu 385-83
[3]. Cochleate structures were obtained from these proteo-
liposomes [4]. Briefly, AFCo1 formation was performed by
diluting precipitated proteoliposomes with detergent. The
detergent was eliminated and calcium buffer (CB), Tris
10mM and 5mM of calcium chloride, was incorporated
using CFS. CFS was used in two steps: firstly, four washes
with CB were carried out to form the cochleates and then
the detergent from the protein solution was removed by
diafiltration to a constant volume [5]. In this system, we
used a hollow fiber from Amicon (polysulfona cartridge
of 10 kDa porosity, 1 mm channel diameter of fiber and
0.45 m2 area of filtration), allowing us to obtain a batch of
upto 20 L. Secondly, the excess calcium and other con-
taminants were eliminated by six diafiltration washes.
Formulations and immunogenicity
AFCo1 formulation contains Neisseria protein 2 mg/ml in
CB and thiomersal preservative at 0.05% (w/v). For co-
administration studies ovalbumin (OVA) or a synthetic
peptide from haemolytic Streptococcus B (PepVacTB1)
were admixed with AFCo1. Each dose of this formulation
contained 50µg of AFCo1 with 20 µg of OVA or 20 µg of
PepVacTB1. Female BALB/c mice (6-8 weeks old, CENPA-
LAB, Cuba) were immunized three times via the intranasal
(i.n) route at 0, 7 and 14 days with 12.5 µL administered
into each nostril. The sera and saliva were collected as pre-
viously described [2] . Serum and saliva antibody titers
(IgG, IgA, and IgG subclasses) were determined by indirect
ELISA [6]. The supernatants of spleen cell cultures were
stimulated in vitro with Neisseria proteoliposomes and
evaluated for cytokine production using ELISA kits from
Pharmingen (San Diego, CA) according to the manufac-
turer’s instructions. The differences between the groups
were evaluated by Graph Pad Prism 4 software.
Preliminary studies of stability
The AFCo1 lots obtained were subjected to preliminary
stability evaluation for 12 months. This study was carried
out at a shelf temperature of 5 ± 3º C and stressed at 40° C.
We also evaluated the chemical physical characteristics of
the obtained AFCo1.
Results
CFS was employed to get large volume batches of AFCo1
Formation of AFCo1, in the first stage, was characterized
by a constant diafiltration flow. However, during the
washing steps (second stage) the flow had a tendency to
increase with the increasing number of washes. The
hydrodynamic behavior of system in this second stage
was unusual, suggesting low membrane-product interac-
tion, which allowed high recirculation flow at low pres-
sures. Using CFS methodology, the AFCo1 were obtained
with high efficiency (more than 80 %, taking into consid-
eration the recovery of the proteins). The batches were
obtained under aseptic conditions.
AFCo1 is an efficient adjuvant of Neisseria
proteoliposome antigens (PLn)
Table 1 shows that AFCo1 obtained by CFS induced high
serum IgG and IgG subclass antibody responses against
antigens in the Neisseria Proteoliposome (anti-PLn) when
administrated by the i.n route. AFCo1 induced significant
(p<0.05) IgG2a and IgG1 anti-PLn titers suggesting a pre-
ferential induction of a Th1-type response. It was also
shown that i.n immunization of mice with AFCo1 induced
IgA antibodies in saliva, on day 7 after the last dose. The i.
n application of AFCo1 was able to induce measurable
levels IgA of anti-PLn in saliva. High levels of IFNg, but no
IL5 productions were also elicited after AFCo1 immuniza-
tion by the i.n route (Table 1); these results confirm that
AFCo1 induce Th1 polarization.
Effect of co-administration of AFCo1 with OVA or
PepVacTB1 antigens
We also explored the adjuvant properties of AFCo1
obtained following vaccination with OVA or PepVacTB1
antigens. High levels of anti-OVA or anti-PepVacTB1 IgA
were detected in saliva when AFCo1 was co-administered
with OVA or PepVacTB1 intranasally. The i.n immunized
mice with AFCo1+OVA developed significant (p<0.01)
amounts of anti-OVA IgG in sera (Table 2). Also signifi-
cant (p<0.01) amounts of anti-PepVacTB1 IgG in sera
were found with i.n co-administration of AFCo1+Pep-
VacTB1 (Table 2). The AFCo1+OVA or PepVacTB1
immunized groups displayed significant (p<0.01) amounts
of serum specific IgG1 and IgG2a antibody by the i.n
route (Table 2).
Preliminary stability studies
The AFCo1 obtained by CFS proved to be stable for a per-
iod of 12 months at a temperature of 5 ± 3°C (shelf life)
and 40°C (stress). This stability study included serial mea-
surement of size, shape, pH, appearance, protein concen-
tration, preservative concentration, identity, microbial
limit, preservative effectiveness and specific anti-PLn IgG
and IgA responses in serum and saliva, respectively. All
parameters and intervals where established as showed in
Table 3. The results of IgA response anti-PLn were not
satisfactory at 6-month (4°C) time point, but were satisfac-
tory after 12 months (Table 3). It is possible that proces-
sing and successive defrosting of these samples destroyed
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the IgA. This antibody is very stable, however changes of
temperature may unfold IgA structure, therefore protocols
to evaluate saliva samples require inhibition of enzymes
mucosal fluids with inhibitors or heating sample by short
times (56°C by 10 minutes) and store them at -70°C until
evaluation [2].
Discussion
Previous studies have demonstrated the production of
AFCo1 on a lab scale and preliminary work at higher
scale demonstrated that CFS could be used to obtain
larger amounts of cochleates [4].
In the present work, the efficiency of the immune
response of the AFCo1 obtained by tangential diafiltra-
tion (pilot scale) was demonstrated. The results suggest
that the i.n route is able to induce significant and antigen
specific IgA levels in saliva and of IgG in serum after
immunization of BALB/c mice with 3 dose of AFCo1.
High titers of IgG1 and IgG2a in serum were also
induced with i.n administration of AFCo1. The i.n
administration with AFCo1 generated a Th1 polarized
pattern, characterized by high levels of IgG2a and induc-
tion of IFNg. This agrees with several reports that suggest
that nasal associated lymphoid tissue is a place where the
induction of Th1 response is favored [7]. In addition, the
immunogenicity and pattern induction of AFCo1
obtained by CFS corresponds with previous results
obtained with AFCo1 obtained by the lab scale dialysis
rotary method [2,8].
In this study we also evaluated the capability of spleno-
cytes obtained from the immunized animals to be stimu-
lated in vitro to produce IFNg. The AFCo1 efficiently
stimulate this cytokine suggesting activation and differen-
tiation of the CD4 lymphocytes (LFT) into Th1 cells.
Considering that this cytokine is produced principally by
the LFT, then IFNg might be produced by Th1 type cells
isolated from spleen [9].
We explored the adjuvant properties of AFCo1 with
addmixed heterologous antigens (OVA or PepVacTB1) via
the i.n route. The results showed that i.n immnunization
with AFCo1+OVA or AFCo1+PepVacTB1 induced high
levels of anti OVA or PepVacTB1 IgG, IgG1 and IgG2a
antibodies in sera and specific IgA in saliva. We have
demonstrated the adjuvant capability of the AFCo1
obtained by CFS when co-administered with heterologous
antigens by the i.n route. Previous studies have shown i.n
immunization with AFCo1 obtained by the dialysis
method has adjuvant effects on co-administered heterolo-
gous antigens such as OVA [8].
In addition, stability studies of AFCo1 were satisfactorily
concluded in order to develop safe formulations for nasal
application. Pharmaceutical and preclinical evaluation of
new adjuvants, as part of vaccine formulations, is relevant
in their efficacy and safety evaluation. Detailed information
about the preclinical experiments with AFCo1 were pre-
viously published by Infante et al.[10]. These authors
demonstrate that AFCo1 successfully passed the tests of
local tolerance and preclinical toxicity (single and repeated
doses). A single dose was classified as non irritating locally
and showed no systemic toxicity, so AFCo1 is considered
potentially non toxic for intranasal administration to
humans in this experiments. Repeated doses experiments,
which included: complete blood count, biochemical and
histopathological tests, showed that AFCo1 was rated as
Table 1 Immunogenicity AFCo1 obtained by CFS and administered by the i.n route: Anti-PLn IgA, IgG and IgG
isotypes measured by ELISA
Groups IgG(U/mL) sera IgA(AU/mL) saliva IgG1(OD) sera IgG2a(OD) sera IFNg(pg/mL)
AFCo1 4415.74* 2147.03* 1.378* 1.62* 2787.04*
Placebo 106.05 101.48 0.102 0.120 162.381
PHA - - - - 3065.34*
Groups of female BALB/c mice (n = 5) were immunized with AFCo1 by the i.n route (3 doses, 12.5µL in each nostril) with a 7 day interval. Anti-PLn IgA in saliva
or serum and anti-PLn IgG and IgG subclass induction by AFCo1 and IFN-g production by spleen cells from immunized mice. Phosphate Buffer was used for the
Placebo group. IFN-g concentration was evaluated in splenocyte supernatants, 7 days after the last dose and stimulated in vitro with PLn or phytohaemagglutinin
(PHA). Asterisks denote significant differences between groups * p<0.05.
Table 2 OVA or PepVacTB1specific antibody responses induced by intranasal administration.
Groups IgG(OD) sera IgA(OD) saliva IgG1(OD) sera IgG2a(OD) sera
I AFCo1+Ova 0.80** 0.63** 1.5** 0.8274**
OVA 0.12 0.11 0.10 0.10
II AFCo1+ PepVacTB1 1.10** 0.45* 1.63** 1.04**
PepVacTB1 0.2 0.1 0.056 0.105
Results of two independent experiments. Experiment I shows the results of co-administration of AFCo1 with OVA and Experiment II shows the results of co-
administration of AFCo1 with PepVacTB1. Female BALB/c mice (n = 5) were inoculated i.n (3 doses with 7 days interval) with AFCo1 (50 µg) admixed with
heterologous antigen OVA or PepVacTB1 (20 µg). Control groups were treated with OVA or PepVacTB1 (20 µg per dose per mouse) alone. The data are
expressed as the OD means of samples measured at 492 nm. Significant differences between the means of different groups were determined. Asterisks denote
significant differences between groups * p<0.05, ** p<0.01
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Table 3 Results of preliminary stability studies
Description Limits 2-8oC 40oC
0 3 6 12 1 3 6
Particle size (light
microscopy)
≥ 60% of under 50 µm S - S S NP NP NP
Shape (light microscopy) elongated tubular structures S - - S NP NP NP
pH 7±0.5 7,4 7,1 7,1 7,1 7,2 7,2 7,3
Appearance Milky suspension S S S S S S S
Free Ca2+ (atomic
absorption)
<5 mM <0,1 <0,1 NP <0,1 - <0,1 <0,3
Protein concentration
(Lowry)
1,2±0,2 mg/mL 1,19 1,26 NP 1,27 1,19 1,2 1,26
Preservative (atomic
absorption)
0.07-0.13 mg/mL 0.1 NP NP 0,09 NP NP NP
Identity (SDS/PAGE) two majority bands between 36 and 46 kDa and two minor between 70 and 85 kDa P P NP P P P P
Microbial limit Less than <102 aerobic bacteria or fungi by Pseudomonas aeruginosam. Absence of Staphylococcus aureus, Escherichia
coli and Salmonella
S S NP NP NP NP NP
Preservative Microbial growth reduction <2 log at 14 days and no microbial growth increased from 14 to 28 days S S NP S S S S
Potency ELISA(IgA) IgA in saliva anti OMV > 250 UA 261.33 503 NS 882.17 NS NS NS
Potency ELISA(IgG) IgG in serum anti OMV S S S S S S S



















non-irritating locally and with no evidence of systemic
toxicity, so it was considered potentially non toxic to
humans by intranasal administration in repeated doses
[10].
New vaccines containing new adjuvants represent a
challenge for regulatory authorities, which are actively
discussing standardization of guidelines to evaluate and
develop adjuvants in the near future [11].
In summary, the present study demonstrates the efficacy
of AFCo1 obtained on pilot scale through the crossflow
system. AFCo1 obtained by this methodology produced
high level of specific antibodies in serum and saliva by the
mucosal route and have the capacity to enhance the
mucosal response against Neisseria antigens in AFCo1
using OVA or PepVacTB1 as model antigens. Tangential
filtration would ensure the production of a large scale
adjuvant that is safe and immunogenic.
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